Pamela Munster
Hematology & Oncology · Regents of the University of California
Credentials: · · ·
History
- Until 2000
- Until 1996
Research
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
New England Journal of Medicine · 2020 · 1,421 citations
Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate
Science Translational Medicine · 2013 · 1,052 citations
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma
Journal of Clinical Oncology · 2008 · 514 citations
25 papers · 2 as a fellow
- DS
15 papers
14 papers · 1 as a fellow
- SM
9 papers
8 papers
8 papers
8 papers
8 papers
Grants
- 1999–2028
National Cancer Institute · P30
Project lead · $670.5K · University of California, San Francisco
- 2022–2027
Integrating Epigenetic Modulation into DNA Damage Repair
National Cancer Institute · R01
Contact PI · $3.2M · University of California, San Francisco
- 2017–2022
National Cancer Institute · R01
Contact PI · $1.8M · University of California, San Francisco
- 2014–2020
Translating HP 13C MRI as a Novel Paradigm for Assessing Drug Target Inhibition
National Cancer Institute · R01
PI · $3.3M · University of California, San Francisco
Clinical trials
- 2022–2028
Principal investigator · Withdrawn · Phase 1
Pamela Munster
- 2022–2032
Pilot Study of Pancreatic Cancer Screening
Principal investigator · Active not recruiting
University of California, San Francisco
- 2021–2025
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
Principal investigator · Withdrawn · Phase 1
Pamela Munster
- 2021–2023
Principal investigator · Terminated · Phase 2
University of California, San Francisco